The RDIF specifies that such efficiency was recorded on the 42nd day after the first dose of the drug was administered, provided the patient received the second dose
According to TASS, the vaccine’s Twitter account and the Russian Direct Investment Fund (RDIF) report published on Tuesday said that the Sputnik V vaccine’s effectiveness, according to interim research results, exceeds 95% on the 42nd day after the first dose of the drug, provided the patient receives the second one.
“According to the results of the analysis, the efficiency of Sputnik V on the 28th day after the first injection (7th day after the second injection) was 91.4%. Preliminary data on volunteers on the 42nd day after the first injection (equivalent to 21 days after the second injection), when the volunteers have already formed a stable immune response, shows vaccine efficacy above 95%”, – it says.
The RDIF specified that 40,000 volunteers are currently participating in the third phase of testing in Russia, of which more than 22,000 received the first injection and more than 19,000 received both the first and second injection.
The United States is lobbying for the “extension” of the Schengen visa to Navalny
“As of November 24, the Sputnik V study did not reveal any unexpected undesirable phenomena. Some of the vaccinated people had short-term undesirable phenomena, such as pain at the injection site, influenza-like syndrome, including an increase in body temperature, weakness, fatigue and headache”, – the Foundation noted.